Adverse outcome group (n=24) | No adverse outcome group (n=67) | p value | |
Age (years) | 63±11.2 | 64±11.6 | 0.804 |
Gender, male/female, n (%) | 18/6 | 53/14 | 0.775 |
Smoker | 16 (66.7) | 34 (50.7) | 0.134 |
Diabetes mellitus | 4 (16.7) | 9 (13.4) | 0.738 |
Initial heart rate (bpm) | 84±18 | 78±18 | 0.309 |
Laboratory data | |||
WBC (per cm3) | 10.5±3.30 | 10.6±3.06 | 0.928 |
Glucose (mg/dl) | 157±52.4 | 152±73.0 | 0.167 |
Serum potassium (mEq/l) | 3.8±0.35 | 3.8±0.36 | 0.968 |
sAA activity (U/ml) | 334±81.0 | 282±110.1 | 0.002* |
Anterolateral infarction, n (%) | 16 (66.7) | 39 (58.2) | 0.627 |
Continuous variables are presented as mean±SD.
Percent values are in parenthesis.
↵* p<0.05 between two groups.
sAA, salivary α-amylase; WBC, white cell.